Appetite regulation, glucose control, insulin sensitivity, energy balance, adipose-tissue biology and fat distribution all intersect here. This category contains some of the strongest human peptide-drug evidence in the Index—alongside some of its most speculative metabolic stories.
Metabolic science is where “peptide” stops being a useful shorthand. Evidence maturity varies enormously.
Body weight can be an important endpoint, but it does not capture the entire metabolic system.
Few Outcome Hubs show a wider evidence spectrum.
A GLP-1 receptor agonist with extensive randomized human evidence and FDA-approved products for diabetes, weight management and cardiovascular-risk reduction in defined populations.
A dual GIP/GLP-1 receptor agonist with large randomized trial programs and FDA-approved products for defined metabolic indications.
An investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, with substantial human trial data but no FDA approval as of this build.
A growth hormone-releasing factor analog with an FDA-approved indication for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
A long-acting amylin analog under clinical development for obesity, including combination strategies with GLP-1 therapy.
A mitochondrial-derived peptide studied for metabolic signaling, exercise adaptation and aging biology; human evidence remains early.
A dual glucagon/GLP-1 receptor agonist in late-stage clinical development for obesity and metabolic liver disease.
A dual GLP-1/glucagon receptor agonist developed for obesity and diabetes, with regional regulatory status differing from the U.S.
Evidence scores are editorial orientation, not treatment rankings. Approval applies to specific products, indications and populations.
GLP-1 and multi-agonist therapies moved metabolic peptides into mainstream culture. Public interest now routinely reaches investigational compounds before approval.
Metabolic health sits at the intersection of therapeutics, behavior, diagnostics and long-term disease risk.
Future coverage follows continuous glucose monitoring, body composition, nutrition, resistance training, sleep, lipid biology, liver health and next-generation obesity therapeutics.
Powerful obesity-trial evidence—and still investigational.
Real human evidence and real approval, with a narrow indication.
Compelling endogenous biology does not automatically establish an injectable metabolic therapy.
Compare evidence maturity and regulatory status across the library.